Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Short-term Investments: 2022-2024

Historic Short-term Investments for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $406.8 million.

  • Day One Biopharmaceuticals' Short-term Investments rose 201.07% to $408.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $408.3 million, marking a year-over-year increase of 201.07%. This contributed to the annual value of $406.8 million for FY2024, which is 200.05% up from last year.
  • As of FY2024, Day One Biopharmaceuticals' Short-term Investments stood at $406.8 million, which was up 200.05% from $135.6 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Short-term Investments ranged from a high of $406.8 million in FY2024 and a low of $135.6 million during FY2023.
  • Over the past 3 years, Day One Biopharmaceuticals' median Short-term Investments value was $257.0 million (recorded in 2022), while the average stood at $266.4 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first slumped by 47.25% in 2023, then skyrocketed by 200.05% in 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' Short-term Investments (Yearly) stood at $257.0 million in 2022, then tumbled by 47.25% to $135.6 million in 2023, then surged by 200.05% to $406.8 million in 2024.